Exploring the Connection Between Alopecia Areata and Hearing Impairment 

by

Overview of Research Objectives  A recent study published in Cureus has shed light on a significant yet less explored domain: the relationship between alopecia areata (AA) and auditory dysfunction. This research seeks to unravel the intricate links between these two conditions, offering new insights into the comprehensive healthcare needs of individuals with AA.  Significance of… Read More

Introduction to Secukinumab’s FDA Approval

by

A Milestone in Hidradenitis Suppurativa Treatment The medical community welcomed a groundbreaking advancement with the FDA’s recent approval of Secukinumab (Cosentyx) for treating hidradenitis suppurativa (HS). This approval marks a significant development, as Secukinumab is the first new biologic therapy for HS in nearly a decade. Hidradenitis suppurativa, a chronic and often debilitating skin condition,… Read More

The Crucial Role of Inclusion Clinical Trials for Equitable Treatment Options

by

Psoriasis affects millions worldwide, with symptoms ranging from mild to severe. Critical to advancing treatments for this diverse condition are clinical trials. They are the engines driving medical innovations, particularly in dermatology. Our focus today is on the study “Differential Patient Travel Distance and Time to Psoriasis Clinical Trial Sites,” which sheds light on the… Read More

Introduction to Shared Decision-Making in Eczema Treatment

by

Eczema, a chronic skin condition, often requires a unique and personalized approach to treatment. It’s not just about finding the right medication or therapy; it’s about building a relationship between healthcare providers (HCPs) and patients. This relationship, founded on trust, empathy, and collaboration, is at the heart of shared decision-making (SDM) – a process that… Read More

The Emergence of TYK2 Inhibitors in Psoriasis Treatment: A Synopsis

by

Key Takeaways: Psoriasis remains undertreated in the US due to factors such as concerns about side effects, monitoring requirements, and the use of injectable treatments. TYK2 inhibitors, like orally administered deucravacitinib, represent a promising new treatment option for psoriasis. Numerous hurdles, including treatment costs, specialist availability, insurance coverage, and safety concerns need addressing for effective… Read More

Understanding Mental Health as a Psoriasis Comorbidity

by

As common as Psoriasis is, the comorbidities associated with Psoriasis are often overlooked by patients and sometimes their physicians. As a part of their Psoriasis comorbidities series, Delaney Drew, and Kristi Hawley, DO have been publishing monthly articles to better identify, understand, and associate these issues. In part 2 published in October, mental health comes… Read More

Research shows link between Zinc Deficiency and Eczema

by

Zinc deficiency has been linked to eczema in ongoing research. While zinc creams and appointments may help soothe skin and reduce itching, they are not a first-choice treatment option for atopic dermatitis. If confirmed through continued research, it would provide a much-needed treatment option for one of the most common skin issues impacting patients around… Read More

The US FDA announces the approval of Dupilumab

by

The US Food and Drug Administration recently announced the approval of dupilumab, a fully human monoclonal antibody that inhibits the signaling of the IL-4 and IL-13 pathways while not suppressing the immune system. It’s the first and only treatment indicated for adults with prurigo nodularis (PN). It has been indicated for atopic dermatitis, asthma, nasal… Read More

Maintaining Remission of Rosacea Through Dermatologist and Patient Partnerships

by

While rosacea is treatable, its complex manifestations require consistent monitoring and treatment adjustments to achieve clear skin. Coordination between the physician and patient is critical to properly identify symptoms and apply the necessary changes throughout the therapy. This extended process often encounters issues when patients fail to express dissatisfaction and stop complying with their assigned… Read More

Promising signs from Novan’s Berdazimer Gel in Phase 3 Trials

by

In Phase 3 of B-SIMPLE 4’s clinical study published in JAMA Dermatology, Novan’s Berdazimer Gel outperformed the placebo significantly in the treatment of Molluscum. If approved, Berdazimer Gel would become the first prescription medication for the virus. Learn more about this development and explore more details about the study in the publication linked below. Novan’s… Read More